Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Study Of Single Agent Gefitinib (Iressa) In Patients With Clinical Stage I Non-Small Cell Lung Cancer (NSCLC) Proceeding To Mediastinoscopy And Surgery

NCT00188617 is registered in ClinicalTrials.gov with University Health Network, Toronto as lead sponsor.

NCT NCT00188617
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00188617 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Study Of Single Agent Gefitinib (Iressa) In Patients With Clinical Stage I Non-Small Cell Lung Cancer (NSCLC) Proceeding To Mediastinoscopy And Surgery
Lead sponsor
University Health Network, Toronto
Phase
Phase 2
Overall status
Completed
Start date
January 31, 2005
Completion date
November 30, 2009
Enrollment
35 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

lung cancer